Home › Funds › MPM BioImpact LLC › RARE
MPM BioImpact LLC position in RARE
ULTRAGENYX PHARMACEUTICAL IN · Health Care
MPM BioImpact LLC reported holding 1,418,215 shares of RARE (ULTRAGENYX PHARMACEUTICAL IN) in its Q2 2026 13F filing — a position valued at US$47.4M, representing 2.89% of its reported portfolio and ranking #12 among its reported holdings. MPM BioImpact LLC has disclosed RARE holdings in 8 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How MPM BioImpact LLC's RARE position evolved
MPM BioImpact LLC first disclosed a stake in RARE in Q1 2024 at 245,590 shares (US$11.5M). The position peaked in Q2 2026 at 1,418,215 shares, worth US$47.4M. Across 8 filings, MPM BioImpact LLC increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,418,215 shares valued at US$47.4M. Notable position changes include a 55% increase in Q2 2024 (shares rose 35% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 245.59K | $11.47M | New |
| Q2 2024 | 380.55K | $15.64M | Add |
| Q3 2024 | 329.73K | $18.32M | Reduce |
| Q4 2024 | 391.02K | $16.45M | Add |
| Q1 2025 | 398.44K | $14.43M | Add |
| Q2 2025 | 395.70K | $14.39M | Reduce |
| Q3 2025 | 395.70K | $11.90M | Hold |
| Q2 2026 | 1.42M | $47.35M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RARE and 13F data
RARE (ULTRAGENYX PHARMACEUTICAL IN) is a Health Care company. 26 other funds we track also report a position in RARE — the largest reported positions include RTW INVESTMENTS, LP (US$260.3M), SANDS CAPITAL MANAGEMENT, LLC (US$105.5M), FRONTIER CAPITAL MANAGEMENT CO LLC (US$95.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RARE
- RTW INVESTMENTS, LP 7.80M sh · $260.34M · Q2 2026
- SANDS CAPITAL MANAGEMENT, LLC 3.16M sh · $105.46M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 2.85M sh · $95.09M · Q2 2026
- Bellevue Group AG 1.98M sh · $66.20M · Q2 2026
More on MPM BioImpact LLC
FAQ
How long has MPM BioImpact LLC held RARE?
MPM BioImpact LLC has disclosed RARE holdings in 8 of the last 10 reported quarters, going back to Q1 2024.
What is MPM BioImpact LLC's current position in RARE?
As of Q2 2026, MPM BioImpact LLC holds 1.42M shares of RARE (ULTRAGENYX PHARMACEUTICAL IN), valued at $47.35M, representing 2.89% of its reported portfolio and ranking #12.
Has MPM BioImpact LLC been buying or selling RARE?
In the latest 13F filing (Q2 2026), MPM BioImpact LLC newly opened its position in RARE. The position peaked in Q2 2026 at 1.42M shares.
Which other funds hold RARE?
Other major institutional holders of RARE include RTW INVESTMENTS, LP, SANDS CAPITAL MANAGEMENT, LLC, FRONTIER CAPITAL MANAGEMENT CO LLC, among 26 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.